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Abstract
Introduction: Radiographic damage is one of the core outcomes in axial SpA and is usually assessed with the
modified Stoke Ankylosing Spondylitis (AS) Spine Score (mSASSS). Alternatively, the Radiographic AS Spinal Score
(RASSS) is proposed, which includes the lower thoracic vertebrae, under the hypothesis that most progression
occurs in these segments. We aimed to compare the mSASSS and RASSS with regard to performance.
Methods: Two-yearly spinal radiographs from patients followed in the Outcome in AS International Study (OASIS)
were used (scored independently by two readers). A total of 195 patients had at least one radiograph (12-year
follow-up) to be included. We assessed the accessibility of vertebral corners (VCs) for scoring, as well as status and
2-year progression scores of both scoring methods. To assess the potential additional value of including the
thoracic segment in the score, the relative contribution (in %) to the 2-year total RASSS progression of each spinal
segment (cervical, thoracic and lumbar) was determined, and compared to the expected contribution, under the
assumption that a balanced segmental progression would occur, proportional to the number of sites per segment.
Results: The mSASSS could be scored in a total of 809 radiographs and the RASSS in 78% of these. In 58% of the
latter, the score was based on one to two available thoracic VCs scores, and the remaining two to three were
imputed because they were missing. There were 520 two-year mSASSS intervals available, and in 63% of them
RASSS progression could be assessed. The mean (SD) 2-year interval progression score (330 intervals) was 2.0 (3.6)
for the mSASSS and 2.4 (4.4) for the RASSS, yielding a similar effect size (mSASSS 0.57 and RASSS 0.55). Exclusive
progression of the thoracic segment occurred in only 5% of the cases. There was no significant difference between
the observed (14%) and expected (16%) contribution to progression of the thoracic segment (P = 0.70).
Conclusions: The determination of RASSS for radiographic damage of the spine is frequently impossible or
strongly influenced by non-contributory imputation. In comparison to the mSASSS, the contribution of thoracic VCs
in the RASSS method is negligible, and does not justify the additional scoring efforts.
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Introduction
Radiographic damage is one of the core outcomes in axial
spondyloarthritis (axial SpA) (including both non-radio-
graphic axial SpA and ankylosing spondylitis (AS)) as
recommended by the Assessment of SpondyloArthritis
international Society (ASAS) [1]. Cross-sectionally, it is
associated with impairment in spinal mobility [2,3] and
longitudinally with functional disability [4], emphasizing
the importance of assessment. ASAS recommends routine
radiography of the lateral cervical and lumbar spine for
assessing damage over time, but radiographs should not
be repeated more frequently than every 2 years, unless
indicated in individual cases, who might show faster pro-
gression [5,6].
Different scoring methods have been developed to quan-
tify structural damage in axial spondyloarthritis: the Bath
AS Radiology Index (BASRI) [7], the Stoke AS Spine Score
(SASSS) [8] and a modification of the SASSS, the mSASSS
[9]. In a formal comparison, the mSASSS has shown best
reliability and sensitivity to change [10]. Consequently, it
is the preferred scoring method for assessing structural
damage in the spine for use in clinical trials, as endorsed
by ASAS and Outcome Measures in Rheumatology Clini-
cal Trials (OMERACT) [11]. The mSASSS assesses the
presence of erosions, sclerosis, squaring, syndesmophytes
and bridges at the anterior vertebral corners (VCs) of both
the cervical and lumbar spine [9].
More recently, a new scoring method, the Radiographic
AS Spinal Score (RASSS), has been proposed that
includes the lower thoracic vertebrae, under the hypoth-
esis that most progression is found in these segments
[12]. Four thoracic VCs are added and the same features
are scored as for the mSASSS, though with slightly modi-
fied scoring rules.
The usefulness of the RASSS has not been further eval-
uated thus far. Hence, it is important to compare both
scoring methods, in order to establish the preferred
method for the assessment of structural damage as an
outcome measure.
Outcome measures should be valid in all their aspects.
To standardize the nomenclature of validity, the OMER-
ACT filter has been proposed and this includes three
aspects: discrimination, truth and feasibility [13]. The
main objective of the present study was to compare the
mSASSS and RASSS with regard to performance, taking
the aspects of the OMERACT filter into account.
Materials and methods
Patients and radiographs
Radiographs from patients included in the Outcome in
Ankylosing Spondylitis International Study (OASIS)
were used [14,15]. The OASIS study is a prevalence
cohort including 217 consecutive patients with AS from
the Netherlands, Belgium and France that started in
1996. According to protocol, cervical and lumbar spine
radiographs were taken biannually for 12 years, with a
total of seven possible time points per patient. For the
present study, patients were included if they had at least
one time point in which at least one of the radiographic
damage scores could be calculated.
Scoring methods
The two scoring methods used were the mSASSS [9] and
the RASSS [12] (Table 1). In the mSASSS the anterior
VCs of the cervical (lower border of C2 to upper border
of T1) and lumbar (lower border of T12 to upper border
of S1) segments (a total of 24 VCs) are scored at a lateral
view, for the presence of erosion and/or sclerosis and/or
squaring (1 point), syndesmophyte (2 points) and brid-
ging syndesmophyte (3 points). The total score ranges
from 0 to 72 [9]. The RASSS is similarly scored as the
mSASSS with 3 modifications: 1) inclusion of the lower
thoracic spine (lower border of T10 to upper border of
T12; total of 28 VCs); 2) erosions are not scored; 3)
squaring is not scored in the cervical spine. The RASSS
ranges from 0 to 84 [12].
The radiographs were independently scored according
to both scoring methods by two trained experts (SR and
CS) who were blinded to demographic and clinical data.
Both readers registered all the changes identified in each
VC (for example, erosions, sclerosis and squaring) sepa-
rately so that afterwards both scores could be computed.
Because radiographs were taken in different formats dur-
ing the 12 years of follow-up, enabling the readers to iden-
tify the points in time, they were scored with known
chronology. All the available films per patient were scored
at the same time.
Only scores of radiographs with ≤ 3 missing VCs per seg-
ment (either cervical or lumbar) were used. For the RASSS,
the same rule applied and the four additional thoracic VCs
were considered part of the lumbar segment [12]. Reliabil-
ity between the two readers was explored using Bland and
Altman analysis [16] on the progression intervals. All
radiographs from patients with at least one score being
beyond the 95% level of agreement were independently
scored by an adjudicator (AvT). Averaged scores per VC of
the two primary readers were used. In adjudicated cases,
the score of the primary reader closest to the adjudicator
was used. Missing VCs were imputed using an adaptation
of the last-observation-carried-forward methodology. First,
a missing value for a VC was replaced with the value of the
previous observation. Then, the mean spinal segment’s
progression score (either cervical or lumbar) per patient
was calculated. This was added to the imputed value, in an
attempt to more accurately reproduce the true progression.
This rule was applied assuring that the score achieved per
VC never exceeded a score of 3. Similarly, in case of a
score missing in a patient with a score of 0 in the same VC
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at a subsequent time point, the score of 0 for the previous
time point(s) was assumed. If the baseline score of a VC
was missing, the same procedure was applied, subtracting
the mean segment progression from the score of year 2 for
a particular patient. If a value of this VC was also missing
at year 2, then an average of the other available VCs from
this spinal segment at baseline was used to replace the
missing VC(s).
Status and progression scores were calculated for both
scoring methods. Status scores refer to the score in each
of the available time points (at baseline and every 2 years
thereafter). Progression scores were calculated as the dif-
ference between the status scores of two time points.
Two-year progression scores refer to the progression
occurring within 2 years, that is, status score of one time
point minus the status score of the immediately previous
time point. Twelve-year progression scores were com-
puted as the score at year 12 minus the score at baseline.
Use of the OMERACT filter to compare the scoring
methods
The mSASSS and the RASSS were judged with respect to
the different aspects of the OMERACT filter: truth, dis-
crimination, and feasibility [13].
Feasibility
The feasibility aspect of the OMERACT filter addresses the
question: can the measure be applied easily, given con-
straints of time, money and interpretability? The feasibility
of both methods (mSASSS and RASSS) was assessed.
Because the RASSS requires a further four additional thor-
acic VCs to be present in the radiograph of the lumbar
spine, the assessment of the ability to obtain both scores is
important. The availability of the VCs and the ability to
assess the status and the 2-year progression scores of both
scoring methods was compared and the number of avail-
able VCs out of the four additional VCs included in the
RASSS was also investigated. Comparisons were performed
calculating a ratio of the available cases for the RASSS over
the mSASSS, taking all radiographs into account, but also
restricted to 1) patients with a RASSS available at year 12
in order to assess whether the RASSS would perform
differently in the subset of patients with a complete follow-
up and 2) patients with the first interval between years 0
and 2 available to compare with other results available in
the literature for the RASSS [12].
Discrimination
The discrimination aspect focuses on the question: does
the measure discriminate between situations of interest?
This aspect of the OMERACT filter pertains to sensitivity
to change and reliability.
Inter-observer reliability was assessed for both status
and progression scores for both mSASSS and RASSS, by
means of Bland and Altman plots [16] and by calculation
of the smallest detectable change (SDC) for each method.
The SDC is the smallest change that can be detected
beyond measurement error to determine change in
an individual and was calculated as follows [17]:




2 . SD diff is the standard
deviation (SD) of the set of differences in change scores
obtained by two readers; k is the number of readers
whose change scores are used (here: k = 2).
To obtain insight into sensitivity to change of the meth-
ods, the means and SDs of baseline, 2-year and 12-year
status scores were assessed. Effect sizes (for all 2-year
progression scores) were calculated for both mSASSS and
RASSS dividing the mean value of the progression scores
by the corresponding standard deviation.
Truth
The truth aspect deals with the question: is the measure
truthful, does it measure what is intended? Is the result
Table 1 Description of the mSASSS and RASSS scoring systems.
mSASSS RASSS
Spinal segments assessed
- Cervical spine Lower border of C2 to upper border of T1 Lower border of C2 to upper border of T1
- Thoracic spine Not included Lower border of T10 to upper border of T12
- Lumbar spine Lower border of T12 to upper border of S1 Lower border of T12 to upper border of S1
Range of scoring system 0-72 0-84
Scoring definitions
- 0 No change No change
- 1 Erosion, squaring, sclerosis Squaring only for the thoracic and lumbar
segments; no erosions scored; sclerosis
scores for all VCs
- 2 Syndesmophytes Syndesmophytes
- 3 Bridging syndesmophytes/ankylosis Bridging syndesmophytes/ankylosis
mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; RASSS, radiographic Ankylosing Spondylitis Spinal Score; C, cervical; T, thoracic; S, sacral.
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unbiased and relevant? Both mSASSS and RASSS are, to
a certain extent, similar, which means that they have a
common part of construct validity. Therefore, we
assessed the potential additional value of including the
thoracic vertebrae in the RASSS, by determining the
relative contribution (in %) to the 2-year total RASSS
progression of each spinal segment (cervical, thoracic
and lumbar) in comparison to the expected contribu-
tion. A balanced segmental progression, proportional to
the number of VCs assessed in the RASSS (twelve cervi-
cal VCs, four thoracic VCs and twelve lumbar VCs) was
assumed. The expected and balanced contribution
assumed was 43% (12/28 VCs) for each of the cervical
and lumbar segments and 14% (4/28 VCs) for the thor-
acic segment.
Statistical analysis
Descriptive statistics were performed, with continuous
variables being presented as mean (SD) and categorical
variables as frequencies. Observed and expected progres-
sion rates were compared using the chi-square test and a
5% level of significance was assumed. Stata SE version
11 was used (Statacorp, College Station, TX, USA).
Results
A total of 195 patients had at least one radiograph that
could be scored (according to the mSASSS and/or RASSS),
64 had a radiograph that could be scored at year 12 and a
total of 520 2-year progression intervals throughout the
12-year follow-up period were available Patients had a
mean age of 42.8 (SD 12.4) years, mean disease duration
since symptom onset of 20.0 (SD 11.6), mean disease
duration since diagnosis of 11 (SD 8.7) years, 71% were
males and 84% HLA-B27 positive. Baseline demographic,
clinical and radiographic characteristics are summarized in
Table 2.
Feasibility
The mSASSS could be scored in a total of 809 radio-
graphs. The RASSS could be calculated in 78% of these
radiographs (n = 629) (Tables 3 and 4). In 58% of those,
in which the RASSS was calculated, the score was based
on one or two available thoracic VC scores and the
remaining two to three needed imputation because they
were missing, so were in fact non-informative. There
were 520 2-year mSASSS interval progression scores
available, and in 63% of them a 2-year RASSS interval
progression score could be determined. If the availability
of all four additional VCs was required, then the RASSS
could only be calculated in 226 (36%) radiographs and in
64 (19%) progression intervals. For the subgroups of
radiographs from patients with the first 2-year interval
available and of radiographs from patients with a RASSS
available at year 12, see Tables 3 and 4.
Discrimination
The first part of the discrimination aspect is reliability.
Figure 1 shows the Bland and Altman plots for the pro-
gression scores of both the mSASSS and RASSS. In
general, both scores could be reliably performed without
clear systematic error. The SDC for the progression scores
was 2.9 for the mSASSS and 3.5 for the RASSS.
Of all radiographs in which both the mSASSS and
RASSS could be determined (n = 629), the mean (SD)
status score was 15.5 (17.9) units for the mSASSS and
18.0 (20.9) units for the RASSS (Table 5). The mean (SD)
2-year progression score, calculated in 330 2-year inter-
vals, was 2.0 (3.6) for the mSASSS and 2.4 (4.4) for the
RASSS. The progression score per spinal segment was
1.2 (2.3) for the cervical segment, 0.8 (2.1) for the lumbar
segment and 0.4 (1.2) for the thoracic segment in the
RASSS. The effect size of the 2-year progression score
was 0.57 (2.0/3.6) for the mSASSS and 0.55 (2.4/4.4) for
the RASSS.
For all radiographs from patients with a RASSS evaluable
at 12-year follow-up (n = 59), the mean (SD) status score
of the mSASSS was 18.0 (19.3) and of the RASSS 20.8
(22.4); and in this group the mean (SD) 2-year progression
Table 2 Baseline demographic, clinical and radiographic
characteristics of the patients included in assessment of
the radiographic progression in this study.
Assessment N = 195*
Age (years) 42.8 (12.4)
Male gender (%) 138 (71%)
HLA-B27 positive (%) 158 (84%)
Symptoms duration (years) 20.4 (12.9)
Disease duration (years) 11.0 (8.7)
ASDAS-CRP 2.7 (1.0)
BASDAI (0-10) 3.4 (2.0)
BASFI (0-10) 3.2 (2.5)
BASMI (0-10) 3.7 (1.5)
CRP (mg/l) (N = 186) 17.5 (23.5)
Elevated CRP (%)‡ 96 (52%)
mSASSS (0-72) (N = 177)¥ 10.8 (15.2)
RASSS (0-84) (N = 130) 11.8 (16.6)
mSASSS of patients with available RASSS (0-72) (N = 130) 10.1 (14.2)
mSASSS > 0 (%) (N = 177) 143 (81%)
RASSS > 0 (%) (N = 130) 107 (82%)
mSASSS > 0 of patients with available RASSS (%) (N = 130) 106 (82%)
*Data are presented as mean (SD) or n (%). N = 195, representing patients
with ≥ 1 radiograph with the mSASSS evaluable throughout follow-up (not
necessarily at baseline available). ‡The cutoff was 10 mg/l for the Dutch
patients (n = 122) and 5 mg/l for the Belgian (n = 23) and French patients (n
= 50); ¥18 patients did not have a radiograph with an mSASSS evaluable at
baseline, but had a radiograph in which the mSASSS could be calculated at a
later time point and were therefore included in the study. ASDAS-CRP,
Ankylosing Spondylitis Disease Activity Score (C-reactive protein); BASDAI,
Bath Ankylosing Spondylitis Disease Activity Score; BASFI, Bath Ankylosing
Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology
Index; CRP, C-reactive protein; mSASSS, modified Stoke Ankylosing Spondylitis
Spine Score; RASSS, radiographic Ankylosing Spondylitis Spinal Score.
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score of the mSASSS was 2.4 (4.5) and of RASSS 2.9 (5.5).
Compared to the status scores of all radiographs, the
status scores of the radiographs from both patients with a
RASSS evaluable at 12-year follow-up and radiographs
with the four additional thoracic VCs available were higher
(Table 5). During the first 2-year follow-up, the progres-
sion was 1.9 (4.1) units for the mSASSS and 2.2 (5.0) units
for the RASSS in patients with available intervals for both
mSASSS and RASSS (n = 134).
In patients with an mSASSS evaluable at baseline and at
12-year follow-up (n = 64), the mean (SD) 12-year pro-
gression was 11.7 (11.5). In 38 out of the 64 patients, the
RASSS could be assessed with a mean 12-year progression
of 14.2 (14.6) and a corresponding mSASSS progression of
12.2 (12.5) in this group.
In patients with a RASSS available at year 12 (n = 59),
the baseline, 2-year and 12-year RASSS status scores were
11.8 (15.3), 12.3 (13.9) and 28.5 (25.0), respectively. For
the mSASSS, the corresponding status scores were 10.6
(13.6), 11.2 (12.4) and 24.5 (21.6), respectively.
Interestingly, in a few cases, the RASSS enabled the
occurrence of negative progression scores. Taking all
radiographs into account, in five VCs in the cervical seg-
ment, first sclerosis was considered to be present and
scored as 1, but at follow-up an erosion appeared, which
was still scored as a 1 in the mSASSS but was scored 0
according to the RASSS scoring rules and, consequently,
the progression score for that specific VC was -1 for
RASSS.
Truth
Exclusive progression in the thoracic segment, which can
only be captured by the RASSS and not by the mSASSS,
occurred in only 5% of the 2-year progression intervals
(17 intervals out of 330). In 2% of the 2-year progression
intervals, a progression of two or more units (possibly
indicating new syndesmophyte formation) in the thoracic
segment was found. In 25% of the intervals (81 out of
330 intervals), progression occurred exclusively in the
cervical segment and in 7% (23 out of 330) in the lumbar
segment. However, there were no significant differences
between the observed and expected contributions of the
thoracic segment to progression (16% vs. 14%, P = 0.70),
whilst progression was observed more frequently than
expected in the cervical spine (55% vs. 43%, P = 0.09),
and less frequently in the lumbar spine (29% vs. 43%, P =
0.04) (Table 6).
Discussion
The present study shows that the mSASSS remains the
most appropriate method for scoring radiographic
Table 3 Feasibility of the mSASSS vs.
All radiographs (n = 809)* All radiographs from
patients with RASSS
available at year 12
(n = 341)*
All baseline radiographs from patients
with baseline - year 2 interval available
(n = 184)*
mSASSS RASSS % RASSS in
radiographs with
mSASSS
mSASSS RASSS % mSASSS RASSS % RASSS in
radiographs with
mSASSS
Available status scores (≤ 3
missing VC per segment)
809 629 78% 341 277 81% 184 134 73%
Available 2-year progression
intervals
520 330 63% 239 159 67% 164 96 59%
RASSS - availability of the status and progression scores.
*n = number of radiographs. mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; RASSS, radiographic Ankylosing Spondylitis Spinal Score; VC, vertebral
corner.
Table 4 Feasibility of the RASSS - availability of the four thoracic vertebral corners added to the RASSS.





available at year 12
(n = 341)*
All baseline radiographs from
patients with baseline - year 2
RASSS interval available
(n = 134)*
N % N % n %
- 1 VC only 65 10% 28 10% 18 13%
- 2 VCs 297 47% 139 50% 71 53%
- 3 VCs 41 7% 18 7% 11 8%
- 4 VCs 226 36% 92 33% 34 25%
*n = number of radiographs. mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; RASSS, radiographic Ankylosing Spondylitis Spinal Score; VC, vertebral
corner.
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progression in patients with AS based on feasibility, dis-
crimination and truth aspects of the OMERACT filter.
With regard to feasibility, the 2-year progression scores
were available for the RASSS in only 63% of the cases in
which mSASSS progression intervals could be calculated.
In the paper describing the RASSS, the authors reported
an availability of 88% of the progression scores within the
first 2 years [12], while in our study only in 59% of the
cases a RASSS progression score could be calculated in
this first 2-year interval. Furthermore, in our study in one
third of the radiographs in which the RASSS could be
calculated, only one to two thoracic VCs were accessible,
meaning that calculation of the RASSS was based on
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Figure 1 Bland and Altman plots: reliability of the mSASSS and RASSS progression scores. Difference against mean for mSASSS and
RASSS progression scores of the two readers. The SDC for the progression scores was 2.9 for the mSASSS and 3.5 for the RASSS. mSASSS,
modified Stoke Ankylosing Spondylitis Spine Score; RASSS, Radiographic Ankylosing Spondylitis Spinal Score; SDC, smallest detectable change.





















STATUS SCORES mSASSS RASSS mSASSS RASSS mSASSS RASSS mSASSS RASSS
Total Score 15.5 (17.9) 18.0 (20.9) 18.0 (19.3) 20.8 (22.4) 17.3 (18.2) 20.5 (21.4) 10.2 (14.2) 11.8 (16.6)
Cervical segment 8.4 (10.1) 7.9 (10.1) 10.0 (10.7) 9.5 (10.7) 8.9 (10.0) 8.3 (10.0) 5.5 (8.2) 5.2 (8.1)
Lumbar segment 7.1 (9.8) 7.1 (9.8) 8.0 (10.0) 8.0 (9.9) 8.4 (10.2) 8.4 (10.2) 4.6 (7.9) 4.6 (7.9)
Lumbar segment (with thoracic segment included) - 10.1 (13.1) - 11.4 (13.2) - 12.2 (13.7) - 6.6 (10.7)
Thoracic segment - 3.0 (3.9) - 3.4 (3.8) - 3.8 (4.4) - 2.0 (3.4)
2-YEAR PROGRESSION SCORES All radiographs with
2-year RASSS intervals




RASSS available at year
12 and with 2-year
RASSS intervals










evaluable (n = 96)
Total Score 2.0 (3.6) 2.4 (4.4) 2.4 (4.5) 2.9 (5.5) 2.1 (3.3) 2.8 (4.2) 1.9 (4.1) 2.2 (5.0)
Cervical segment 1.2 (2.2) 1.2 (2.3) 1.5 (2.6) 1.4 (2.9) 1.2 (2.0) 1.1 (1.9) 1.0 (2.6) 0.9 (2.9)
Lumbar segment 0.8 (2.0) 0.8 (2.1) 1.0 (2.4) 1.0 (2.4) 0.9 (2.2) 0.9 (2.2) 0.9 (2.2) 0.9 (2.2)
Lumbar segment (with thoracic segment included) - 1.2 (2.8) - 1.5 (3.3) - 1.6 (3.3) - 1.3 (3.1)
Thoracic segment - 0.4 (1.2) - 0.5 (1.2) - 0.7 (1.7) - 0.4 (1.4)
*Data are expressed as mean (SD). mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; RASSS, radiographic Ankylosing Spondylitis Spinal Score; SD,
standard deviation, VC, vertebral corner.
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lumbar spine. This shows that an important number of
radiographs obtained in the Netherlands, France and
Belgium does not include the lower part of the thoracic
spine, in contrast to what has been suggested for Germany
[12]. According to the OMERACT filter, feasibility
captures an essential element in the selection of measures,
one that may be decisive in determining a measure’s
success [13]. The worse feasibility of the RASSS compared
with the mSASSS jeopardizes its wide use.
The RASSS demonstrated a higher mean progression,
but an increase in the variance of the progression scores
was also observed, resulting in similar effect sizes between
mSASSS and RASSS. A higher mean progression was
expected because the RASSS includes four additional VCs
compared with the mSASSS, so that the RASSS is by defi-
nition almost always higher than the mSASSS. Exceptions
are only the cases with erosions in any segment or squar-
ing in the cervical spine, which are scored for the mSASSS,
but not for the RASSS. Nevertheless, and comparing the
progression scores with the limited data available in the
literature for the RASSS, our RASSS progression scores
were higher. In the first 2 years, we found a progression in
the RASSS of 2.2 (5.0), whereas Baraliakos et al. reported a
2-year progression of 1.6 (2.8) [12]. Also, our mSASSS
progression scores were higher compared with the same
study (1.9 (4.1) vs. 0.9 (2.5)) [12]. A possible explanation
for the difference in progression scores can be the differ-
ence in baseline radiographic damage (baseline mSASSS
of 8.1 (14.6) in German cohort vs. 10.2 (14.2) in OASIS
cohort). It is well known that presence of radiographic
damage is a predictor of further and faster progression of
radiographic damage [18-20]. Other literature on RASSS
progression scores is currently lacking. However, our
mSASSS progression scores can be compared with other
available studies. There are reports of 2-year mSASSS pro-
gression scores of around 1 mSASSS unit [21-23], 2.5
units [18] and 2.6 units (extrapolation to a 2-year period
of the annual progression rate of 1.3 (2.5), and assuming
linearity) [20]. The differences between scores can be
attributed to differences in selection of patients, baseline
radiographic damage of patients, conditions in which
radiographs were read [24] or the method of imputation
of missing VCs. The increase in the variance around the
progression scores resulted in similar effect sizes for both
methods (0.57 for the mSASSS and 0.55 for the RASSS),
showing that the higher mean progression of the RASSS is
offset by the increased noise. For discrimination, both
scoring methods seemed to be reliable, however, the SDC
for the mSASSS was slightly smaller compared to the
RASSS (2.9 vs. 3.5), suggesting that the measurement
error with the RASSS is somewhat higher. Reliability of
the RASSS could possibly improve by having an additional
and separate radiograph to score the thoracic VCs. This
could reduce the parallax associated with extending the
view of the lumbar radiograph to include the thoracic
VCs, but would on the other hand imply higher costs and
radiation for the patients. With regard to the truth aspect
of the OMERACT filter, we found that most progression
occurred in the cervical segment of the spine (55%), fol-
lowed by the lumbar spine (29%) and only 16% was found
in the thoracic vertebrae. Furthermore, the progression in
the thoracic vertebrae was not significantly different from
what was expected, if progression throughout the spine
would occur in a balanced way. In addition, we showed
that new syndesmophytes exclusively occurring in the
thoracic spine occurred in a maximum of 2% of the inter-
vals. These data should be interpreted with caution,
because a progression score of 2 does not always corre-
spond to a new syndesmophyte, but can also mean twice a
score of 1 in two separate VCs, reflecting development of
squaring or sclerosis. This shows that the RASSS does not
capture more progression occurring in the thoracic verteb-
rae, as was hypothesized by Baraliakos et al. [12]. In our
study, a 2-year progression in the thoracic vertebrae of 0.4
(1.4) out of a total RASSS progression of 2.2 (5.0)) was
found. Baraliakos et al. reported a progression of 0.6 (3.3)
out of a total RASSS progression of 1.6 (2.8), indicating a
higher contribution from the thoracic VCs to the total
RASSS. The reason for this discrepancy between both stu-
dies is not entirely clear, but availability of the thoracic
VCs for scoring can play a role.
Some limitations of the present study should be
addressed. Films were obtained throughout a 12-year fol-
low-up, which means that some of them were old and did
not have the optimal quality. Nevertheless, this limited the
reading of both scoring methods similarly. Furthermore,
the findings of this study may not be generalizable to
countries where lumbar radiographs routinely include the
low thoracic spine, which is not standard procedure in our
three countries.
Table 6 Ratio of 2-year progression in each of the spinal segments of the RASSS.
Relative contribution in each of the spinal segments of the RASSS (in %) P value for the difference
Expected Observed
Cervical segment (12 VCs) 43% 55% 0.09
Lumbar segment (12 VCs) 43% 29% 0.04
Thoracic segment (4 VCs) 14% 16% 0.70
*n = 330 represents progression intervals. RASSS, radiographic Ankylosing Spondylitis Spinal Score; NA, not applicable.
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Conclusions
In conclusion, the calculation of RASSS for status or pro-
gression of radiographic abnormalities in the spine is
frequently impossible or strongly influenced by non-
contributory imputation. The effect size of both methods
is similar. In comparison to the mSASSS, the contribution
of thoracic VCs in the RASSS is negligible, and does not
justify the additional scoring efforts. The mSASSS remains
the most appropriate measure to assess radiographic
damage in patients with AS.
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